HALO logo
halo search icon
ProKidney Corp. Class A

US$1.69

Price Change Indicator
0.14 (9.03%)
ProKidney Corp. Class A
PROK · NAS

ProKidney Corp. Class A

Start Trading PROK for Free

US$1.69

Price Arrow0.14 (9.03%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusBig Candle (Realtime)HALO AllHALO Consensus ValueRecent Earnings upgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ProKidney Corp. Class A Overview

PROK Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Neutral

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Strong

Balance Sheet

Neutral

About PROK

icon

Website

ProKidney Corp. Class A

icon

Telephone

1.336.999.7028

icon

Address

Suite 250, 2000 Frontis Plaza Boulevard, Winston-Salem, NC 27103

Description

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

PROK Price Chart

Key Stats

Market Cap

US$220.08M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.54 - 7.13

Trade Value (12mth)

US$3,782,605.00

1 week

-6.63%

1 month

-25.84%

YTD

-30.49%

1 year

100.99%

All time high

14.19

Key Fundamentals

EPS 3 yr Growth

-70.70%

EBITDA Margin

NaN%

Operating Cashflow

-$120m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

NaN

Quick Ratio

9.10

Other Data

Shares Outstanding (Fully Diluted)

142m

HALO Sector

Other Finance

Next Company Report Date

25-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

PROK Announcements

Latest Announcements

DateAnnouncements
16 May 26
16 May 26
16 May 26
16 May 26
16 May 26

PROK Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-0.57-0.62-0.52locklocklock
EPS (Fully Diluted)
 $locklocklocklock-0.57-0.62-0.52locklocklock
Growth
 %locklocklocklock67.3-8.717.6locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of ProKidney Corp. Class A (PROK:NAS)?
Halo FAQ
The current share price of ProKidney Corp. Class A (PROK:NAS) is USD$1.69.
What is the 52-week high share price for ProKidney Corp. Class A (PROK:NAS)?
Halo FAQ
The 52-week high share price for ProKidney Corp. Class A (PROK:NAS) is USD$7.13.
What is the 52-week low share price for ProKidney Corp. Class A (PROK:NAS)?
Halo FAQ
The 52-week low share price for ProKidney Corp. Class A (PROK:NAS) is USD$0.54.
What is the dividend yield for ProKidney Corp. Class A (PROK:NAS)?
Halo FAQ
ProKidney Corp. Class A (PROK:NAS) does not pay a dividend.
What was ProKidney Corp. Class A (PROK:NAS) last dividend payment?
Halo FAQ
ProKidney Corp. Class A (PROK:NAS) does not pay a dividend.
What is the franking level for ProKidney Corp. Class A (PROK:NAS)?
Halo FAQ
ProKidney Corp. Class A (PROK:NAS) has a franking level of 0.00%.
In which sector is ProKidney Corp. Class A (PROK:NAS) classified?
Halo FAQ
ProKidney Corp. Class A (PROK:NAS) is classified in the Other Finance.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial